Mesoblast - ADR Peer Comparison
$12.28
$-0.27
(-2.15%)
As on 23-Oct-2026 16:00EDT
Market cap
$1,595 Mln
Revenue (TTM)
$121 Mln
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Edit
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,595 | 2,698 | 2,496 | 793 | 666 |
Revenue ($ Mln) |
121 | 450 | 549 | 366 | 4 |
Net Profit ($ Mln) |
-57.76 | -188.21 | 17.88 | 9.27 | -187.89 |
Net Margin (%) |
-47.60 | -41.86 | 3.26 | 2.53 | -4,613.11 |
RoE (%) |
-9.91 | -28.46 | 1.43 | 3.39 | -233.88 |
Price to Earnings |
-- | -- | 143.60 | 86.15 | -- |
Price-To-Book |
3.65 | 4.56 | 2.25 | 2.95 | 19.54 |
Income Statement ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Operating Revenue
|
120.79 | -- | -- | -- | -- |
|
Cost of Revenue
|
19.21 | -- | -- | -- | -- |
|
Gross Profit
|
101.58 | -- | -- | -- | -- |
|
Operating Expenses
|
153.08 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
-51.50 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-57.14 | -- | -- | -- | -- |
|
Provision for Tax
|
0.62 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
-57.76 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
568.41 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
123.56 | -- | -- | -- | -- |
|
Current Liabilities
|
81.11 | -- | -- | -- | -- |
|
Total Liabilities
|
773.08 | -- | -- | -- | -- |
Assets ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
575.59 | -- | -- | -- | -- |
|
Current Assets
|
197.49 | -- | -- | -- | -- |
|
Total Assets
|
773.08 | -- | -- | -- | -- |
|
Total Debt*
|
127.33 | -- | -- | -- | -- |
|
Net Current Assets
|
116.38 | -- | -- | -- | -- |
Cashflow ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-43.83 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-1.02 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
-15.33 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-8.13 | -- | -- | -- | -- |
|
ROE (%)
|
-9.91 | -- | -- | -- | -- |
|
ROA (%)
|
-7.42 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-47.82 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
6.02 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
43.45 | -- | -- | -- | -- |
|
EPS Growth (%)
|
0.45 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-30.40 | -- | -- | -- | -- |
|
Price / Book Value
|
3.09 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-42.81 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.22 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.02 | -- | -- | -- | -- |
|
Current Ratio
|
2.43 | -- | -- | -- | -- |
|
Quick Ratio
|
2.09 | -- | -- | -- | -- |
|
Interest Coverage
|
-2.15 | -- | -- | -- | -- |
Operating Efficiency Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
47.74 | -- | -- | -- | -- |
|
Asset Turnover
|
0.16 | -- | -- | -- | -- |
|
Receivable days
|
109.66 | -- | -- | -- | -- |
|
Inventory Days
|
478.70 | -- | -- | -- | -- |
|
Payable days
|
509.43 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
78.92 | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
